胰岛素联合胰高血糖素样肽受体激动剂对糖尿病患者体重指数的影响及对胰岛素敏感性改善的效果  

Effect of Insulin Combined with Glucagon-like Peptide-1 Receptor Ago⁃nist on Body Mass Index and Improvement of Insulin Sensitivity in Pa⁃tients with Diabetes Mellitus

作　　者：张锐 赵伟伟 ZHANG Rui;ZHAO Weiwei(Department of Pharmacy,Liaocheng City Third People´s Hospital,Liaocheng,Shandong,252000,China)

机构地区：[1]聊城市第三人民医院药学部,山东聊城252000

出　　处：《中外医疗》2025年第2期6-9,共4页China & Foreign Medical Treatment

摘　　要：目的 分析胰岛素联合胰高血糖素样肽(glucagon-like peptide-1,GLP-1)受体激动剂对糖尿病患者体重指数的影响及胰岛素敏感性的改善效果。方法 回顾性选取2022年1月—2023年6月聊城市第三人民医院收治的112例糖尿病肥胖患者的临床资料,根据不同治疗方式分为两组,每组56例。对照组予以胰岛素治疗,观察组予以胰岛素联合GLP-1受体激动剂治疗。6个月后,比较两组患者的临床疗效、血糖水平、体重指数、胰岛素敏感性。结果 观察组治疗总有效率为98.21%(55/56),高于对照组的85.71%(48/56),差异有统计学意义(χ^(2)=4.350,P=0.037)。观察组血糖水平均低于对照组,体重指数低于对照组,葡萄糖输注率高于对照组,差异均有统计学意义(P均<0.05)。结论 糖尿病患者实施胰岛素联合GLP-1受体激动剂治疗可取得显著效果,不仅能提高其临床疗效,改善血糖水平,而且还能降低体重指数,增强胰岛素敏感性。Objective To analyze the effects of insulin combined with glucagon-like peptide-1(GLP-1)receptor agonists on body mass index and insulin sensitivity in diabetic patients.Methods The clinical data of 112 diabetic obese patients admitted to Liaocheng Third People´s Hospital from January 2022 to June 2023 were retrospectively selected and divided into two groups according to different treatment methods,with 56 cases in each group.The control group was treated with insulin,and the observation group was treated with insulin combined with GLP-1 receptor agonist.After 6 months,the clinical efficacy,blood glucose level,body mass index and insulin sensitivity of the two groups were compared.Results The total effective rate of the observation group was 98.21%(55/56),higher than that of the control group 85.71%(48/56),the difference was statistically significant(χ^(2)=4.350,P=0.037).The blood glucose level,body mass index of observation group were all lower than control group,glucose infusion rate of observation group was higher than the control group,and the differences were statistically significant(all P<0.05).Conclusion Insulin combined with GLP-1 receptor agonist can achieve significant effect in diabetic patients,which can not only improve the clinical efficacy and blood glucose level,but also reduce the body mass index and enhance insulin sensitivity.

关 键 词：胰岛素 胰高血糖素样肽受体激动剂 糖尿病 体重指数 

分 类 号：R587.1[医药卫生—内分泌]